|
2600 N. Stemmons Fwy., Ste. 176 Dallas, TX 75207 TX Tel. 214-905-5100 Fax 214-905-5101 |
Type: Public
On the web:
http://www.accesspharma.com
Employees:
9
Employee growth: (40.0%)
Access Pharmaceuticals is looking for ways to give drugs direct and effective access to the parts of the body that need treatment. The company develops drug-delivery systems for application in cancer treatment. Oral treatment MuGard, which is used to reduce mouth inflammation in chemotherapy patients, has received marketing approval from the FDA. Its lead development product is ProLindac, a polymer platinate chemotherapy drug designed to target tumors. Other products in development include oral delivery systems and treatments for diabetes and cancer. The company added several anti-cancer candidates, including a monoclonal antibody, with the 2008 acquisition of Somanta Pharmaceuticals.
Key numbers for fiscal year ending December, 2008:
Sales: $0.3M
One year growth: 410.5%
Net income: ($17.2)M
Officers:
Chairman: Steven H. Rouhandeh
CEO and Director: Jeffrey B. Davis
VP, CFO, Treasurer, and Secretary: Stephen B. Thompson
Competitors:
Biovail
Bristol-Myers Squibb
Endo Pharmaceuticals
